24/7 Patient Assistance: 760-405-8205
Pasi A. Janne, MD
Conditions Treated Lung Cancer Ovarian Cancer Pleural Mesothelioma Testicular Mesothelioma
specialties & services
Dr. Janne is a well respected associate professor of medicine at Harvard Medical School, and is also practicing as a medical oncologist specializing in mesothelioma at the Brigham and Women's Hospital in Boston. He started his medical career by attending the courses of the University of Pennsylvania School of Medicine completing residency at the Brigham and Women's Hospital. Later Dr. Janne completed a fellowship at the Dana Farber Cancer institute, well known all over the world for a very effective team of specialists focusing on improving modern cancer treatment techniques. Dr. Pasi Janne is board certified in internal medicine and medical oncology.
University of Pennsylvania - School of Medicine
Brigham and Women\'s Hospital
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
Brigham and Women's Hospital
75 Francis StRead More
Dana-Farber Cancer Institute
450 Brookline Ave.Read More
Massachusetts General Hospital Cancer Center
55 Fruit StRead More
North Shore Medical Center
81 Highland AveRead More
Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
Pasi A. Jänne, Geoffrey Kim, Alice T. Shaw, Rajeshwari Sridhara, Richard Pazdur, Amy E. McKeeSee more >>
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.
Paweletz CP1, Sacher AG2, Raymond CK3, Alden RS2, O'Connell A1, Mach SL2, Kuang Y1, Gandhi L2, Kirschmeier P1, English JM1, Lim LP3, Jänne PA4, Oxnard GR5.See more >>
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer.
Wilson FH1, Johannessen CM2, Piccioni F2, Tamayo P2, Kim JW1, Van Allen EM1, Corsello SM1, Capelletti M3, Calles A3, Butaney M3, Sharifnia T1, Gabriel SB2, Mesirov JP2, Hahn WC1, Engelman JA4, Meyerson M5, Root DE2, Jänne PA6, Garraway LA7.See more >>
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.
Montero J1, Sarosiek KA1, DeAngelo JD1, Maertens O2, Ryan J1, Ercan D1, Piao H1, Horowitz NS3, Berkowitz RS3, Matulonis U1, Jänne PA3, Amrein PC4, Cichowski K2, Drapkin R3, Letai A5.See more >>
American Society of Clinical Oncology